ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01124526
Recruitment Status : Completed
First Posted : May 17, 2010
Last Update Posted : May 17, 2010
Sponsor:
Information provided by:
Asociacion Espanola de Hematologia y Hemoterapia

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : July 2007
  Actual Study Completion Date : July 2008